Device Speedband Superview Super 7_endo

Speedband Superview Super 7

Payments companies reported to CMS as associated with Speedband Superview Super 7. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2,521associated payments (2023-2025)
62clinicians with associated payments
1company reporting

By year

2023 $116
2024 $1,768
2025 $637

Payments reported as associated with Speedband Superview Super 7, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Gastroenterology (Internal Medicine) $1,575
Family $201
Anesthesiology $127
Anatomic Pathology & Clinical Pathology $108
Psychiatry $108
Internal Medicine $86.73

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Speedband Superview Super 7

These are the largest totals companies reported as associated with Speedband Superview Super 7. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Dominique Howard Washington, DC Gastroenterology (Internal Medicine) $108.49
Henry Bell Columbia, MD Anatomic Pathology & Clinical Pathology $108.49
Marvin Lawrence Laurel, MD Gastroenterology (Internal Medicine) $108.49
Ramsey Daher Washington, DC Gastroenterology (Internal Medicine) $108.49
Samuel Muench Bethesda, MD Gastroenterology (Internal Medicine) $108.49
Michael Weinstein Rockville, MD Gastroenterology (Internal Medicine) $108.49
Julio Salcedo Washington, DC Gastroenterology (Internal Medicine) $108.49
Zaifi Shanavas Silver Spring, MD Gastroenterology (Internal Medicine) $108.49
Steven Zeddun Washington, DC Gastroenterology (Internal Medicine) $108.49
Lorenzo Norris Washington, DC Psychiatry $108.49

Prescribed Speedband Superview Super 7?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.